DOI: 10.12890/2026_007356

Atezolizumab-induced myasthenia gravis in metastatic hepatocellular carcinoma: a case report and literature review

Authors

  • Rajani Gubbala Department of Critical Care and Internal Medicine, Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, India 0009-0008-9593-2885
  • Arumugam Ponnuswamy Department of Critical Care and Internal Medicine, Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, India 0009-0008-9696-3907
  • Nikhileshwar C. Reddy Department of Neurology, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, India 0000-0002-3093-327X
  • Sanath Kandem Department of Medical Oncology, Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, India 0009-0006-7337-8970
  • Nikhil Pathi Department of Medical Oncology, Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, India 0000-0002-4570-2028
  • Senthil J. Rajappa Department of Medical Oncology, Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, India 0000-0002-5597-756X

armugamp@gmail.com

Keywords

Immune-related adverse events, myasthenia gravis, atezolizumab, hepatocellular carcinoma, neurotoxicity

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the management of advanced malignancies but are associated with immune-related adverse events (irAEs), including rare neurological complications. We report a case of a 60-year-old male with metastatic hepatocellular carcinoma who developed severe myasthenia gravis (MG) following treatment with atezolizumab and bevacizumab. The patient was diagnosed with multifocal hepatocellular carcinoma in April 2025 and initiated on combination therapy with atezolizumab (1200 mg) and bevacizumab (600 mg) in May 2025. Approximately 2 weeks after receiving the first treatment cycle, he developed progressive fatigability, breathlessness, and dysphagia.
During hospitalization, he experienced acute respiratory deterioration leading to cardiac arrest, requiring successful resuscitation and intensive care support. Subsequently, he developed unexplained hypercapnic respiratory failure during ventilator weaning attempts. Neuroimaging and cerebrospinal fluid analysis were unremarkable. Repetitive nerve stimulation demonstrated a postsynaptic neuromuscular junction disorder, and serum acetylcholine receptor antibodies were positive. A diagnosis of ICI-induced MG was established. The patient was treated with intravenous immunoglobulin, corticosteroids, and pyridostigmine. Despite therapy, respiratory failure persisted, necessitating prolonged ventilator support. His clinical course was further complicated by myocarditis, demyelinating motor-sensory axonal polyradiculoneuropathy, and sepsis, and he ultimately succumbed to his illness. This case highlights the importance of early recognition and prompt management of neurological irAEs, particularly in patients presenting with unexplained respiratory failure after initiation of ICI therapy.

View the entire article

Downloads

References

  1. National Comprehensive Cancer Network. Management of immunotherapy-related toxicities. NCCN Clinical Practice Guidelines in Oncology. Version 2025.
  2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64. doi: 10.1038/nrc3239.
  3. Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1):319. doi: 10.1186/s40425-019-0774-y.
  4. Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018;91(10):e985-e994. doi: 10.1212/WNL.0000000000006124 Erratum in: Neurology. 2019;93(6):280. doi: 10.1212/WNL.0000000000007380.
  5. Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis. Front Neurol. 2020;11:634. doi: 10.3389/fneur.2020.00634.
  6. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128-136. doi: 10.1016/j.ejca.2017.05.041.
  7. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Erratum in: J Clin Oncol. 2022;40(3):315. doi: 10.1200/JCO.21.02786.
  8. Kobayashi Y, Nagamatsu K, Shimizu Y, Nakayama A, Sekijima Y. Atezolizumab-induced myasthenia gravis and myositis: a fatal case report and review of the literature. Int Cancer Conf J. 2025;14(4):428-432. doi: 10.1007/s13691-025-00791-w.
  9. Samar MR, Naviwala MSS, Abdy FR, Shahzadi M. Atezolizumab-induced neuromuscular syndrome mimicking myasthenia gravis in a patient with hepatocellular carcinoma - an area of concern. Ecancermedicalscience. 2025;19:1949. doi: 10.3332/ecancer.2025.1949.
  10. Thakolwiboon S, Karukote A, Wilms H. De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma. Cureus. 2019;11(6):e5002. doi: 10.7759/cureus.5002.

Published

2026-08-24

Issue

Vol. 13 No. 9 (2026)

Categories

How to Cite

1.
Gubbala R, Ponnuswamy A, Reddy NC, Kandem S, Pathi N, Rajappa SJ. Atezolizumab-induced myasthenia gravis in metastatic hepatocellular carcinoma: a case report and literature review. EJCRIM [Internet]. 2026 Aug. 24 [cited 2026 Nov. 3];13(9). Available from: https://ejcrim.com/index.php/ejcrim/article/view/7356